Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...

This was the stock's second consecutive day of gains.

Regeneron’s gene therapy for otoferlin-related ... The result comes from a phase 1/2 study of the company’s experimental adeno-associated virus (AAV) gene therapy DB-OTO and was seen in ...

Peptide-drug Conjugate Market Report Introduction 2 Peptide-drug Conjugate Market Executive Summary 3 Competitive Landscape ...